Literature DB >> 17899297

Optimizing dual-time and serial positron emission tomography and single photon emission computed tomography scans for diagnoses and therapy monitoring.

Joseph A Thie1.   

Abstract

INTRODUCTION: A region's early and late tracer uptake activities, QE and QL, within a dual-time scan (i.e. using two frames) or in serial scans (as for monitoring therapeutic response), are popular quantitative diagnostic aids, especially in oncology. In this paper, maximum performance is sought from their joint use.
METHODS: QL/QnE is introduced as a tumor marker with an empirical n. This generalizes traditional data weighting having n=1 for QL/QE, the retention index (RI), with its associated % difference. Using patient data, iterative guessing finds an optimal n that maximizes a measure of diagnostic performance: D=(difference of normal and abnormal marker means)/(their combined SD), which may be computed from values of QL/QnE, as well as of QL, QE, and RI each used alone. For 2-deoxy-2-[F-18]fluoro-D-glucose(FDG)-positron emission tomography (PET) dual-time protocols, another approach to optimization-selection of scan times-is investigated by simulations using the Sokolov model.
RESULTS: A meta-analysis of 12 PET and single photon emission computed tomography (SPECT) studies with various tracers, cancers, and scan classes (dual-time or serial) finds ns from 0.5 to 1.1. The optimal D necessarily exceeds the best (or any) computed using QE, QL, or RI: negligibly to by as much as 0.6 (or 1.5). The increases in optimal receiver operating curve area (Az) over the best (or any) traditional marker range from negligible to 0.07 (or 0.4). QE alone usually has the lowest D and Az. Statistically significant performance improvement of QL/QnE over QE and QL is shown for most studies. Contrasting with an optimal n, another value n0 can also be found where D=0. Occasionally, n0 can be close to 1, and RI then will have a small D and poor performance. Simulation with kinetic modeling of FDG dual-time scans for liver and liver metastases demonstrates worst and best scan times. Indicated for these imaging protocols are QE at very early cellular transport associated times and QL rather late when phosphorylation/dephosphorylation dominate. Benefits from choosing optimal times in dual-time protocols, especially in combination with choosing optimal ns, can be significant.
CONCLUSION: A protocol-dependent optimizing parameter n in an improved classification marker can easily be identified in a learning set of scans having normals and abnormals. Finding this parameter below 1.0 in most all studies suggests that a popularly used QL/QE may often overweight early activities. Additionally, QL/QE may sometimes be a poor marker choice and underestimate a protocol's diagnostic capability. Subsequent use of the proposed QL/QnE in settings similar to that of the learning set gives improved diagnostic performance over traditional approaches, although by widely varying amounts. Additionally, a method of seeking optimal scan times is demonstrated and suggests significant gains in dual-time protocol performances are possible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17899297     DOI: 10.1007/s11307-007-0111-6

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  19 in total

Review 1.  FDG uptake, tumour characteristics and response to therapy: a review.

Authors:  T A Smith
Journal:  Nucl Med Commun       Date:  1998-02       Impact factor: 1.690

2.  Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.

Authors:  Aysegul Akgun; Gursel Cok; Inanc Karapolat; Tuncay Goksel; Zeynep Burak
Journal:  Ann Nucl Med       Date:  2006-05       Impact factor: 2.668

3.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

4.  Differentiating histologic malignancy of primary brain tumors: pentavalent technetium-99m-DMSA.

Authors:  T Hirano; H Otake; T Shibasaki; M Tamura; K Endo
Journal:  J Nucl Med       Date:  1997-01       Impact factor: 10.057

5.  18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.

Authors:  Alexander M Spence; Mark Muzi; David A Mankoff; S Finbarr O'Sullivan; Jeanne M Link; Thomas K Lewellen; Barbara Lewellen; Pam Pham; Satoshi Minoshima; Kristin Swanson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2004-10       Impact factor: 10.057

6.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.

Authors:  Alexander Matthies; Marc Hickeson; Andrew Cuchiara; Abass Alavi
Journal:  J Nucl Med       Date:  2002-07       Impact factor: 10.057

7.  FDG-PET scanning after radiation can predict tumor regrowth three months later.

Authors:  Izumi Koike; Motoko Ohmura; Masaharu Hata; Nobukazu Takahashi; Takashi Oka; Ichiro Ogino; Jin Lee; Tomoko Umezawa; Kazuhiro Kinbara; Kiichi Watai; Yukihiko Ozawa; Tomio Inoue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

8.  Noninvasive determination of local cerebral metabolic rate of glucose in man.

Authors:  S C Huang; M E Phelps; E J Hoffman; K Sideris; C J Selin; D E Kuhl
Journal:  Am J Physiol       Date:  1980-01

9.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.

Authors:  S Okazumi; K Isono; K Enomoto; T Kikuchi; M Ozaki; H Yamamoto; H Hayashi; T Asano; M Ryu
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057

10.  Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.

Authors:  Stephanie E Stafford; Julie R Gralow; Erin K Schubert; Kristine J Rinn; Lisa K Dunnwald; Robert B Livingston; David A Mankoff
Journal:  Acad Radiol       Date:  2002-08       Impact factor: 3.173

View more
  3 in total

1.  Dual-time-point FDG-PET/CT for the detection of hepatic metastases.

Authors:  Albert Dirisamer; Benjamin S Halpern; Wolfgang Schima; Martin Heinisch; Florian Wolf; Mohsen Beheshti; Franz Dirisamer; Michael Weber; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2008-08-16       Impact factor: 3.488

2.  Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.

Authors:  Ching-yee Oliver Wong; Daniel Noujaim; Hungsen F Fu; Wen-sheng Huang; Cheng-yi S Cheng; Joseph Thie; Ishani Dalal; Chih-yung Chang; Conrad Nagle
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

3.  Time sensitivity factor of single pulmonary nodule: a new cancer characteristic metabolic parameter by (18) F-FDG PET.

Authors:  Ching-Yuan Cheng; Kwo-Whei Lee; Chiang-Hsuan Lee; Yeu-Sheng Tyan; Cheng-Yi Cheng; Jhi-Joung Wang; Chao-Wei Yang; Wen-Sheng Huang; Ching-Yee Oliver Wong
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.